



US008509869B2

(12) **United States Patent**
Baker, Jr. et al.

(10) **Patent No.:** **US 8,509,869 B2**
(45) **Date of Patent:** **Aug. 13, 2013**

(54) **METHOD AND APPARATUS FOR
DETECTING AND ANALYZING VARIATIONS
IN A PHYSIOLOGIC PARAMETER**

(75) Inventors: **Clark R. Baker, Jr.**, Newman, CA (US);
Paul D. Mannheimer, Danville, CA
(US)

(73) Assignee: **Covidien LP**, Mansfield, MA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 1112 days.

(21) Appl. No.: **12/467,003**

(22) Filed: **May 15, 2009**

(65) **Prior Publication Data**
US 2010/0292548 A1 Nov. 18, 2010

(51) **Int. Cl.**
A61B 5/00 (2006.01)

(52) **U.S. Cl.**
USPC **600/323**

(58) **Field of Classification Search**
USPC 128/204.23, 204.18, 204.26, 205.24;
600/309, 310, 323, 338, 328, 330, 300, 301;
604/66; 709/201

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,638,640 A	2/1972	Shaw
3,721,813 A	3/1973	Condon et al.
4,586,513 A	5/1986	Hamaguri
4,603,700 A	8/1986	Nichols et al.
4,621,643 A	11/1986	New, Jr. et al.
4,653,498 A	3/1987	New, Jr. et al.
4,685,464 A	8/1987	Goldberger et al.
4,694,833 A	9/1987	Hamaguri
4,697,593 A	10/1987	Evans et al.

4,700,708 A	10/1987	New, Jr. et al.
4,714,080 A	12/1987	Edgar, Jr. et al.
4,714,341 A	12/1987	Hamaguri et al.
4,759,369 A	7/1988	Taylor
4,770,179 A	9/1988	New, Jr. et al.
4,773,422 A	9/1988	Isaacson et al.
4,776,339 A	10/1988	Schreiber
4,781,195 A	11/1988	Martin
4,796,636 A	1/1989	Branstetter et al.
4,800,495 A	1/1989	Smith

(Continued)

FOREIGN PATENT DOCUMENTS

DE	3405444	8/1985
DE	69123448	5/1997

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 12/165,230, filed Jun. 30, 2008, Baker, Jr.


(Continued)

Primary Examiner — Brian Szmal

(57) **ABSTRACT**

The present disclosure is generally directed to identifying and/or analyzing high resolution variations in a measured physiologic parameter, such as blood oxygen saturation (SpO₂) measured using pulse oximetry. Present embodiments may include a system including a sensor comprising an emitter capable of emitting light at different wavelengths into a tissue bed, and a detector capable of detecting the light from the emitter after dispersion and/or reflection by the tissue bed. Further, the system may include a pulse oximeter capable of receiving signals from the sensor that are indicative of characteristics of the light detected by the detector, and utilizing the signals to estimate blood oxygen saturation values over time at a high resolution to facilitate detection of variations in the blood oxygen saturation values that are smaller in magnitude than an accuracy, display precision, and/or calibration of the blood oxygen saturation values.

17 Claims, 5 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

4,800,885 A	1/1989	Johnson	5,140,989 A	8/1992	Lewis et al.
4,802,486 A	2/1989	Goodman et al.	5,152,296 A	10/1992	Simons
4,805,623 A	2/1989	Jobsis	5,154,175 A	10/1992	Gunther
4,807,630 A	2/1989	Malinouskas	5,158,082 A	10/1992	Jones
4,807,631 A	2/1989	Hersh et al.	5,167,230 A	12/1992	Chance
4,819,646 A	4/1989	Cheung et al.	5,170,786 A	12/1992	Thomas et al.
4,819,752 A	4/1989	Zelin	5,188,108 A	2/1993	Secker
4,824,242 A	4/1989	Frick et al.	5,190,038 A	3/1993	Polson et al.
4,825,872 A	5/1989	Tan et al.	5,193,542 A	3/1993	Missanelli et al.
4,825,879 A	5/1989	Tan et al.	5,193,543 A	3/1993	Yelderman
4,830,014 A	5/1989	Goodman et al.	5,203,329 A	4/1993	Takatani et al.
4,832,484 A	5/1989	Aoyagi et al.	5,209,230 A	5/1993	Swedlow et al.
4,846,183 A	7/1989	Martin	5,213,099 A	5/1993	Tripp
4,848,901 A	7/1989	Hood, Jr.	5,216,598 A	6/1993	Branstetter et al.
4,854,699 A	8/1989	Edgar, Jr.	5,217,012 A	6/1993	Young et al.
4,859,056 A	8/1989	Prosser et al.	5,217,013 A	6/1993	Lewis et al.
4,859,057 A	8/1989	Taylor et al.	5,218,962 A	6/1993	Mannheimer et al.
4,863,265 A	9/1989	Flower et al.	5,224,478 A	7/1993	Sakai et al.
4,865,038 A	9/1989	Rich et al.	5,226,417 A	7/1993	Swedlow et al.
4,867,557 A	9/1989	Takatani et al.	5,228,440 A	7/1993	Chung et al.
4,869,253 A	9/1989	Craig, Jr. et al.	5,237,994 A	8/1993	Goldberger
4,869,254 A	9/1989	Stone et al.	5,239,185 A	8/1993	Ito et al.
4,880,304 A	11/1989	Jaeb et al.	5,246,002 A	9/1993	Prosser
4,883,055 A	11/1989	Merrick	5,246,003 A	9/1993	DeLonzor
4,883,353 A	11/1989	Hausman et al.	5,247,931 A	9/1993	Norwood
4,890,619 A	1/1990	Hatschek	5,247,932 A	9/1993	Chung et al.
4,892,101 A	1/1990	Cheung et al.	5,249,576 A	10/1993	Goldberger et al.
4,901,238 A	2/1990	Suzuki et al.	5,253,645 A	10/1993	Friedman et al.
4,908,762 A	3/1990	Suzuki et al.	5,253,646 A	10/1993	Delpy et al.
4,911,167 A	3/1990	Corenman et al.	5,259,381 A	11/1993	Cheung et al.
4,913,150 A	4/1990	Cheung et al.	5,259,761 A	11/1993	Schnettler et al.
4,926,867 A	5/1990	Kanda et al.	5,263,244 A	11/1993	Centa et al.
4,927,264 A	5/1990	Shiga et al.	5,267,562 A	12/1993	Ukawa et al.
4,928,692 A	5/1990	Goodman et al.	5,267,563 A	12/1993	Swedlow et al.
4,934,372 A	6/1990	Corenman et al.	5,273,036 A	12/1993	Kronberg et al.
4,936,679 A	6/1990	Mersch	5,275,159 A	1/1994	Griebel
4,938,218 A	7/1990	Goodman et al.	5,279,295 A	1/1994	Martens et al.
4,942,877 A	7/1990	Sakai et al.	5,285,783 A	2/1994	Secker
4,948,248 A	8/1990	Lehman	5,285,784 A	2/1994	Secker
4,955,379 A	9/1990	Hall	5,287,853 A	2/1994	Vester et al.
4,960,126 A	10/1990	Conlon et al.	5,291,884 A	3/1994	Heinemann et al.
4,964,408 A	10/1990	Hink et al.	5,297,548 A	3/1994	Pologe
4,971,062 A	11/1990	Hasebe et al.	5,299,120 A	3/1994	Kaestle
4,972,331 A	11/1990	Chance	5,299,570 A	4/1994	Hatschek
4,974,591 A	12/1990	Awazu et al.	5,309,908 A	5/1994	Friedman et al.
5,007,423 A	4/1991	Branstetter et al.	5,311,865 A	5/1994	Mayeux
5,025,791 A	6/1991	Niwa	5,313,940 A	5/1994	Fuse et al.
RE33,643 E	7/1991	Isaacson et al.	5,323,776 A	6/1994	Blakeley et al.
5,028,787 A	7/1991	Rosenthal et al.	5,329,922 A	7/1994	Atlee, III
5,035,243 A	7/1991	Muz	5,337,744 A	8/1994	Branigan
5,040,039 A	8/1991	Hattori et al.	5,339,810 A	8/1994	Ivers et al.
5,054,488 A	10/1991	Muz	5,343,818 A	9/1994	McCarthy et al.
5,055,671 A	10/1991	Jones	5,343,869 A	9/1994	Pross et al.
5,058,588 A	10/1991	Kaestle	5,348,003 A	9/1994	Caro
5,065,749 A	11/1991	Hasebe et al.	5,348,004 A	9/1994	Hollub et al.
5,066,859 A	11/1991	Karkar et al.	5,349,519 A	9/1994	Kaestle
5,069,213 A	12/1991	Polczynski	5,349,952 A	9/1994	McCarthy et al.
5,078,136 A	1/1992	Stone et al.	5,349,953 A	9/1994	McCarthy et al.
5,084,327 A	1/1992	Stengel	5,351,685 A	10/1994	Potratz
5,088,493 A	2/1992	Giannini et al.	5,353,799 A	10/1994	Chance
5,090,410 A	2/1992	Saper et al.	5,355,880 A	10/1994	Thomas et al.
5,094,239 A	3/1992	Jaeb et al.	5,355,882 A	10/1994	Ukawa et al.
5,094,240 A	3/1992	Muz	5,361,758 A	11/1994	Hall et al.
5,099,841 A	3/1992	Heinonen et al.	5,365,066 A	11/1994	Krueger, Jr. et al.
5,099,842 A	3/1992	Mannheimer et al.	5,368,025 A	11/1994	Young et al.
H1039 H	4/1992	Tripp et al.	5,368,026 A	11/1994	Swedlow et al.
5,104,623 A	4/1992	Miller	5,368,224 A	11/1994	Richardson et al.
5,109,849 A	5/1992	Goodman et al.	5,372,136 A	12/1994	Steuer et al.
5,111,817 A	5/1992	Clark et al.	5,377,675 A	1/1995	Ruskewicz et al.
5,113,861 A	5/1992	Rother	5,385,143 A	1/1995	Aoyagi
5,119,815 A	6/1992	Chance	5,387,122 A	2/1995	Goldberger et al.
5,122,974 A	6/1992	Chance	5,390,670 A	2/1995	Centa et al.
5,125,403 A	6/1992	Culp	5,392,777 A	2/1995	Swedlow et al.
5,127,406 A	7/1992	Yamaguchi	5,398,680 A	3/1995	Polson et al.
5,131,391 A	7/1992	Sakai et al.	5,402,777 A	4/1995	Warring et al.
			5,411,023 A	5/1995	Morris, Sr. et al.
			5,411,024 A	5/1995	Thomas et al.
			5,413,099 A	5/1995	Schmidt et al.
			5,413,100 A	5/1995	Barthelemy et al.

5,413,101 A	5/1995	Sugiura	5,676,141 A	10/1997	Hollub
5,413,102 A	5/1995	Schmidt et al.	5,678,544 A	10/1997	DeLonzor et al.
5,417,207 A	5/1995	Young et al.	5,680,857 A	10/1997	Pelikan et al.
5,421,329 A	6/1995	Casciani et al.	5,685,299 A	11/1997	Diab et al.
5,425,360 A	6/1995	Nelson	5,685,301 A	11/1997	Klomhaus
5,425,362 A	6/1995	Siker et al.	5,687,719 A	11/1997	Sato et al.
5,427,093 A	6/1995	Ogawa et al.	5,687,722 A	11/1997	Tien et al.
5,429,128 A	7/1995	Cadell et al.	5,692,503 A	12/1997	Kuenstner
5,429,129 A	7/1995	Lovejoy et al.	5,692,505 A	12/1997	Fouts
5,431,159 A	7/1995	Baker et al.	5,709,205 A	1/1998	Bukta
5,431,170 A	7/1995	Mathews	5,713,355 A	2/1998	Richardson et al.
5,437,275 A	8/1995	Amundsen et al.	5,724,967 A	3/1998	Venkatachalam
5,438,986 A	8/1995	Disch et al.	5,727,547 A	3/1998	Levinson et al.
5,448,991 A	9/1995	Polson et al.	5,730,124 A	3/1998	Yamauchi
5,452,717 A	9/1995	Branigan et al.	5,731,582 A	3/1998	West
5,465,714 A	11/1995	Scheuing	393,830 A	4/1998	Tobler et al.
5,469,845 A	11/1995	DeLonzor et al.	5,743,260 A	4/1998	Chung et al.
RE35,122 E	12/1995	Corenman et al.	5,743,263 A	4/1998	Baker, Jr.
5,474,065 A	12/1995	Meathrel et al.	5,746,206 A	5/1998	Mannheimer
5,482,034 A	1/1996	Lewis et al.	5,746,697 A	5/1998	Swedlow et al.
5,482,036 A	1/1996	Diab et al.	5,752,914 A	5/1998	DeLonzor et al.
5,483,646 A	1/1996	Uchikoga	5,755,226 A	5/1998	Carim et al.
5,485,847 A	1/1996	Baker, Jr.	5,758,644 A	6/1998	Diab et al.
5,490,505 A	2/1996	Diab et al.	5,760,910 A	6/1998	Lepper, Jr. et al.
5,490,523 A	2/1996	Isaacson et al.	5,766,125 A	6/1998	Aoyagi et al.
5,491,299 A	2/1996	Naylor et al.	5,766,127 A	6/1998	Pologe et al.
5,494,032 A	2/1996	Robinson et al.	5,769,785 A	6/1998	Diab et al.
5,497,771 A	3/1996	Rosenheimer	5,772,587 A	6/1998	Gratton et al.
5,499,627 A	3/1996	Steuer et al.	5,774,213 A	6/1998	Trebino et al.
5,503,148 A	4/1996	Pologe et al.	5,776,058 A	7/1998	Levinson et al.
5,505,199 A	4/1996	Kim	5,776,059 A	7/1998	Kaestle
5,507,286 A	4/1996	Solenberger	5,779,630 A	7/1998	Fein et al.
5,511,546 A	4/1996	Hon	5,779,631 A	7/1998	Chance
5,517,988 A	5/1996	Gerhard	5,782,237 A	7/1998	Casciani et al.
5,520,177 A	5/1996	Ogawa et al.	5,782,756 A	7/1998	Mannheimer
5,521,851 A	5/1996	Wei et al.	5,782,757 A	7/1998	Diab et al.
5,522,388 A	6/1996	Ishikawa et al.	5,782,758 A	7/1998	Ausec et al.
5,524,617 A	6/1996	Mannheimer	5,786,592 A	7/1998	Hök
5,529,064 A	6/1996	Rall et al.	5,790,729 A	8/1998	Pologe et al.
5,533,507 A	7/1996	Potratz et al.	5,792,052 A	8/1998	Isaacson et al.
5,551,423 A	9/1996	Sugiura	5,795,292 A	8/1998	Lewis et al.
5,551,424 A	9/1996	Morrison et al.	5,797,841 A	8/1998	DeLonzor et al.
5,553,614 A	9/1996	Chance	5,800,348 A	9/1998	Kaestle
5,553,615 A	9/1996	Carim et al.	5,800,349 A	9/1998	Isaacson et al.
5,555,882 A	9/1996	Richardson et al.	5,803,910 A	9/1998	Potratz
5,558,096 A	9/1996	Palatnik	5,807,246 A	9/1998	Sakaguchi et al.
5,560,355 A	10/1996	Merchant et al.	5,807,247 A	9/1998	Merchant et al.
5,564,417 A	10/1996	Chance	5,807,248 A	9/1998	Mills
5,575,284 A	11/1996	Athan et al.	5,810,723 A	9/1998	Aldrich
5,575,285 A	11/1996	Takanashi et al.	5,810,724 A	9/1998	Gronvall
5,577,500 A	11/1996	Potratz	5,813,980 A	9/1998	Levinson et al.
5,582,169 A	12/1996	Oda et al.	5,817,008 A	10/1998	Rafert et al.
5,584,296 A	12/1996	Cui et al.	5,817,009 A	10/1998	Rosenheimer et al.
5,588,425 A	12/1996	Sackner et al.	5,817,010 A	10/1998	Hibl
5,588,427 A	12/1996	Tien	5,818,985 A	10/1998	Merchant et al.
5,590,652 A	1/1997	Inai	5,820,550 A	10/1998	Polson et al.
5,595,176 A	1/1997	Yamaura	5,823,950 A	10/1998	Diab et al.
5,596,986 A	1/1997	Goldfarb	5,823,952 A	10/1998	Levinson et al.
5,611,337 A	3/1997	Bukta	5,827,182 A	10/1998	Raley et al.
5,617,852 A	4/1997	MacGregor	5,830,135 A	11/1998	Bosque et al.
5,619,992 A	4/1997	Guthrie et al.	5,830,136 A	11/1998	DeLonzor et al.
5,626,140 A	5/1997	Feldman et al.	5,830,137 A	11/1998	Scharf
5,630,413 A	5/1997	Thomas et al.	5,830,139 A	11/1998	Abreu
5,632,272 A	5/1997	Diab et al.	5,831,598 A	11/1998	Kauffert et al.
5,632,273 A	5/1997	Suzuki	5,839,439 A	11/1998	Nierlich et al.
5,634,459 A	6/1997	Gardosi	RE36,000 E	12/1998	Swedlow et al.
5,638,593 A	6/1997	Gerhardt et al.	5,842,979 A	12/1998	Jarman et al.
5,638,818 A	6/1997	Diab et al.	5,842,981 A	12/1998	Larsen et al.
5,645,059 A	7/1997	Fein et al.	5,842,982 A	12/1998	Mannheimer
5,645,060 A	7/1997	Yorkey et al.	5,846,190 A	12/1998	Woehrle
5,645,440 A	7/1997	Tobler et al.	5,851,178 A	12/1998	Aronow
5,660,567 A	8/1997	Nierlich et al.	5,851,179 A	12/1998	Ritson et al.
5,662,105 A	9/1997	Tien	5,853,364 A	12/1998	Baker, Jr. et al.
5,662,106 A	9/1997	Swedlow et al.	5,860,919 A	1/1999	Kiani-Azarbayjany et al.
5,666,952 A	9/1997	Fuse et al.	5,865,736 A	2/1999	Baker, Jr. et al.
5,671,529 A	9/1997	Nelson	5,871,442 A	2/1999	Madarasz et al.
5,673,692 A	10/1997	Schulze et al.	5,873,821 A	2/1999	Chance et al.
5,673,693 A	10/1997	Solenberger	5,879,294 A	3/1999	Anderson et al.
5,676,139 A	10/1997	Goldberger et al.	5,885,213 A	3/1999	Richardson et al.

5,890,929 A	4/1999	Mills et al.	6,133,994 A	10/2000	Mathews et al.
5,891,021 A	4/1999	Dillon et al.	6,134,460 A	10/2000	Chance
5,891,022 A	4/1999	Pologe	6,135,952 A	10/2000	Coetzee
5,891,024 A	4/1999	Jarman et al.	6,144,444 A	11/2000	Haworth et al.
5,891,025 A	4/1999	Buschmann et al.	6,144,867 A	11/2000	Walker et al.
5,891,026 A	4/1999	Wang et al.	6,144,868 A	11/2000	Parker
5,902,235 A	5/1999	Lewis et al.	6,149,481 A	11/2000	Wang et al.
5,910,108 A	6/1999	Solenberger	6,150,951 A	11/2000	Olejniczak
5,911,690 A	6/1999	Rall	6,151,107 A	11/2000	Schöllermann et al.
5,912,656 A	6/1999	Tham et al.	6,151,516 A	11/2000	Kiani-Azarbayjany et al.
5,913,819 A	6/1999	Taylor et al.	6,151,518 A	11/2000	Hayashi
5,916,154 A	6/1999	Hobbs et al.	6,152,754 A	11/2000	Gerhardt et al.
5,916,155 A	6/1999	Levinson et al.	6,154,667 A	11/2000	Miura et al.
5,919,133 A	7/1999	Taylor et al.	6,157,850 A	12/2000	Diab et al.
5,919,134 A	7/1999	Diab	6,163,715 A	12/2000	Larsen et al.
5,920,263 A	7/1999	Huttenhoff et al.	6,165,005 A	12/2000	Mills et al.
5,921,921 A	7/1999	Potratz et al.	6,173,196 B1	1/2001	Delonzor et al.
5,922,607 A	7/1999	Bernreuter	6,178,343 B1	1/2001	Bindzus et al.
5,924,979 A	7/1999	Swedlow et al.	6,181,958 B1	1/2001	Steuer et al.
5,924,980 A	7/1999	Coetzee	6,181,959 B1	1/2001	Schöllermann et al.
5,924,982 A	7/1999	Chin	6,184,521 B1	2/2001	Coffin, IV et al.
5,924,985 A	7/1999	Jones	6,188,470 B1	2/2001	Grace
5,934,277 A	8/1999	Mortz	6,192,260 B1	2/2001	Chance
5,934,925 A	8/1999	Tobler et al.	6,195,575 B1	2/2001	Levinson
5,940,182 A	8/1999	Lepper, Jr. et al.	6,198,951 B1	3/2001	Kosuda et al.
5,954,644 A	9/1999	Dettling et al.	6,206,830 B1	3/2001	Diab et al.
5,960,610 A	10/1999	Levinson et al.	6,213,952 B1	4/2001	Finarov et al.
5,961,450 A	10/1999	Merchant et al.	6,217,523 B1	4/2001	Amano et al.
5,961,452 A	10/1999	Chung et al.	6,222,189 B1	4/2001	Misner et al.
5,964,701 A	10/1999	Asada et al.	6,226,539 B1	5/2001	Potratz
5,971,930 A	10/1999	Elghazzawi	6,226,540 B1	5/2001	Bernreuter et al.
5,978,691 A	11/1999	Mills	6,229,856 B1	5/2001	Diab et al.
5,978,693 A	11/1999	Hamilton et al.	6,230,035 B1	5/2001	Aoyagi et al.
5,983,122 A	11/1999	Jarman et al.	6,233,470 B1	5/2001	Tsuchiya
5,987,343 A	11/1999	Kinast	6,236,871 B1	5/2001	Tsuchiya
5,991,648 A	11/1999	Levin	6,236,872 B1	5/2001	Diab et al.
5,995,855 A	11/1999	Kiani et al.	6,240,305 B1	5/2001	Tsuchiya
5,995,856 A	11/1999	Mannheimer et al.	6,253,097 B1	6/2001	Aronow et al.
5,995,858 A	11/1999	Kinast	6,253,098 B1	6/2001	Walker et al.
5,995,859 A	11/1999	Takahashi	6,256,523 B1	7/2001	Diab et al.
5,997,343 A	12/1999	Mills et al.	6,256,524 B1	7/2001	Walker et al.
5,999,834 A	12/1999	Wang et al.	6,261,236 B1	7/2001	Grimblatov
6,002,952 A	12/1999	Diab et al.	6,263,221 B1	7/2001	Chance et al.
6,005,658 A	12/1999	Kaluza et al.	6,263,222 B1	7/2001	Diab et al.
6,006,120 A	12/1999	Levin	6,263,223 B1	7/2001	Shepherd et al.
6,011,985 A	1/2000	Athan et al.	6,266,546 B1	7/2001	Steuer et al.
6,011,986 A	1/2000	Diab et al.	6,266,547 B1	7/2001	Walker et al.
6,014,576 A	1/2000	Raley et al.	6,272,363 B1	8/2001	Casciani et al.
6,018,673 A	1/2000	Chin et al.	6,278,522 B1	8/2001	Lepper, Jr. et al.
6,018,674 A	1/2000	Aronow	6,280,213 B1	8/2001	Tobler et al.
6,022,321 A	2/2000	Amano et al.	6,280,381 B1	8/2001	Malin et al.
6,023,541 A	2/2000	Merchant et al.	6,285,894 B1	9/2001	Oppelt et al.
6,026,312 A	2/2000	Shemwell et al.	6,285,895 B1	9/2001	Ristolainen et al.
6,026,314 A	2/2000	Amerov et al.	6,285,896 B1	9/2001	Tobler et al.
6,031,603 A	2/2000	Fine et al.	6,298,252 B1	10/2001	Kovach et al.
6,035,223 A	3/2000	Baker, Jr.	6,308,089 B1	10/2001	Von der Ruhr et al.
6,036,642 A	3/2000	Diab et al.	6,312,393 B1	11/2001	Abreu
6,041,247 A	3/2000	Weckstrom et al.	6,321,100 B1	11/2001	Parker
6,044,283 A	3/2000	Fein et al.	6,330,468 B1	12/2001	Scharf
6,047,201 A	4/2000	Jackson, III	6,334,065 B1	12/2001	Al-Ali et al.
6,061,584 A	5/2000	Lovejoy et al.	6,339,715 B1	1/2002	Bahr et al.
6,064,898 A	5/2000	Aldrich	6,343,223 B1	1/2002	Chin et al.
6,064,899 A	5/2000	Fein et al.	6,343,224 B1	1/2002	Parker
6,067,462 A	5/2000	Diab et al.	6,349,228 B1	2/2002	Kiani et al.
6,073,038 A	6/2000	Wang et al.	6,351,658 B1	2/2002	Middleman et al.
6,078,833 A	6/2000	Hueber	6,353,750 B1	3/2002	Kimura et al.
6,081,735 A	6/2000	Diab et al.	6,356,774 B1	3/2002	Bernstein et al.
6,081,742 A	6/2000	Amano et al.	6,360,113 B1	3/2002	Dettling
6,083,157 A	7/2000	Noller	6,360,114 B1	3/2002	Diab et al.
6,083,172 A	7/2000	Baker, Jr. et al.	6,361,501 B1	3/2002	Amano et al.
6,088,607 A	7/2000	Diab et al.	6,363,269 B1	3/2002	Hanna et al.
6,094,592 A	7/2000	Yorkey et al.	6,370,408 B1	4/2002	Merchant et al.
6,095,974 A	8/2000	Shemwell et al.	6,370,409 B1	4/2002	Chung et al.
6,104,938 A	8/2000	Huiku et al.	6,374,129 B1	4/2002	Chin et al.
6,112,107 A	8/2000	Hannula	6,377,829 B1	4/2002	Al-Ali et al.
6,113,541 A	9/2000	Dias et al.	6,381,479 B1	4/2002	Norris
6,115,621 A	9/2000	Chin	6,381,480 B1	4/2002	Stoddart et al.
6,120,460 A	9/2000	Abreu	6,385,471 B1	5/2002	Mortz
6,122,535 A	9/2000	Kaestle et al.	6,385,821 B1	5/2002	Modgil et al.

6,388,240	B2	5/2002	Schulz et al.	6,606,512	B2	8/2003	Muz et al.
6,393,310	B1	5/2002	Kuenstner	6,615,064	B1	9/2003	Aldrich
6,397,091	B2	5/2002	Diab et al.	6,615,065	B1	9/2003	Barrett et al.
6,397,092	B1	5/2002	Norris et al.	6,618,042	B1	9/2003	Powell
6,397,093	B1	5/2002	Aldrich	6,618,602	B2	9/2003	Levin et al.
6,400,971	B1	6/2002	Finarov et al.	6,622,034	B1	9/2003	Gorski et al.
6,400,972	B1	6/2002	Fine	6,622,095	B2	9/2003	Kobayashi et al.
6,402,690	B1	6/2002	Rhee et al.	6,628,975	B1	9/2003	Fein et al.
6,408,198	B1	6/2002	Hanna et al.	6,631,281	B1	10/2003	Kästle
6,411,832	B1	6/2002	Guthermann	6,643,530	B2	11/2003	Diab et al.
6,411,833	B1	6/2002	Baker, Jr. et al.	6,643,531	B1	11/2003	Katarow
6,415,236	B2	7/2002	Kobayashi et al.	6,647,279	B2	11/2003	Pologe
6,419,671	B1	7/2002	Lemberg	6,647,280	B2	11/2003	Bahr et al.
6,421,549	B1	7/2002	Jacques	6,650,917	B2	11/2003	Diab et al.
6,430,423	B2	8/2002	DeLonzor et al.	6,650,918	B2	11/2003	Terry
6,430,513	B1	8/2002	Wang et al.	6,654,621	B2	11/2003	Palatnik et al.
6,430,525	B1	8/2002	Weber et al.	6,654,622	B1	11/2003	Eberhard et al.
6,434,408	B1	8/2002	Heckel	6,654,623	B1	11/2003	Kästle
6,438,399	B1	8/2002	Kurth	6,654,624	B2	11/2003	Diab et al.
6,449,501	B1	9/2002	Reuss	6,658,276	B2	12/2003	Kiani et al.
6,453,183	B1	9/2002	Walker	6,658,277	B2	12/2003	Wasserman
6,453,184	B1	9/2002	Hyogo et al.	6,662,033	B2	12/2003	Casciani et al.
6,456,862	B2	9/2002	Benni	6,665,551	B1	12/2003	Suzuki
6,461,305	B1	10/2002	Schnall	6,668,182	B2	12/2003	Hubelbank
6,463,310	B1	10/2002	Swedlow et al.	6,668,183	B2	12/2003	Hicks et al.
6,463,311	B1	10/2002	Diab	6,671,526	B1	12/2003	Aoyagi et al.
6,466,808	B1	10/2002	Chin et al.	6,671,528	B2	12/2003	Steuer et al.
6,466,809	B1	10/2002	Riley	6,671,530	B2	12/2003	Chung et al.
6,470,199	B1	10/2002	Kopotic et al.	6,671,531	B2	12/2003	Al-Ali et al.
6,470,200	B2	10/2002	Walker et al.	6,671,532	B1	12/2003	Fudge et al.
6,480,729	B2	11/2002	Stone	6,675,031	B1	1/2004	Porges et al.
6,490,466	B1	12/2002	Fein et al.	6,678,543	B2	1/2004	Diab et al.
6,496,711	B1	12/2002	Athan et al.	6,681,126	B2	1/2004	Solenberger
6,498,942	B1	12/2002	Esenaliev et al.	6,681,128	B2	1/2004	Steuer et al.
6,501,974	B2	12/2002	Huiku	6,681,454	B2	1/2004	Modgil et al.
6,501,975	B2	12/2002	Diab et al.	6,684,090	B2	1/2004	Ali et al.
6,505,060	B1	1/2003	Norris	6,684,091	B2	1/2004	Parker
6,505,061	B2	1/2003	Larson	6,694,160	B2	2/2004	Chin
6,505,133	B1	1/2003	Hanna et al.	6,697,653	B2	2/2004	Hanna
6,510,329	B2	1/2003	Heckel	6,697,655	B2	2/2004	Sueppel et al.
6,510,331	B1	1/2003	Williams et al.	6,697,656	B1	2/2004	Al-Ali
6,512,937	B2	1/2003	Blank et al.	6,697,658	B2	2/2004	Al-Ali
6,515,273	B2	2/2003	Al-Ali	RE38,476	E	3/2004	Diab et al.
6,519,484	B1	2/2003	Lovejoy et al.	6,699,194	B1	3/2004	Diab et al.
6,519,486	B1	2/2003	Edgar, Jr. et al.	6,699,199	B2	3/2004	Asada et al.
6,519,487	B1	2/2003	Parker	6,701,170	B2	3/2004	Stetson
6,525,386	B1	2/2003	Mills et al.	6,702,752	B2	3/2004	Dekker
6,526,300	B1	2/2003	Kiani et al.	6,707,257	B2	3/2004	Norris
6,526,301	B2	2/2003	Larsen et al.	6,708,049	B1	3/2004	Berson et al.
6,541,756	B2	4/2003	Schulz et al.	6,709,402	B2	3/2004	Dekker
6,542,764	B1	4/2003	Al-Ali et al.	6,711,424	B1	3/2004	Fine et al.
6,546,267	B1	4/2003	Sugiura et al.	6,711,425	B1	3/2004	Reuss
6,549,795	B1	4/2003	Chance	6,714,803	B1	3/2004	Mortz
6,553,241	B2	4/2003	Mannheimer et al.	6,714,804	B2	3/2004	Al-Ali et al.
6,553,242	B1	4/2003	Sarussi	6,714,805	B2	3/2004	Jeon et al.
6,553,243	B2	4/2003	Gurley	RE38,492	E	4/2004	Diab et al.
6,556,852	B1	4/2003	Schulze et al.	6,719,686	B2	4/2004	Coakley et al.
6,560,470	B1	5/2003	Pologe	6,719,705	B2	4/2004	Mills
6,564,077	B2	5/2003	Mortara	6,720,734	B2	4/2004	Norris
6,564,088	B1	5/2003	Soller et al.	6,721,584	B2	4/2004	Baker, Jr. et al.
6,571,113	B1	5/2003	Fein et al.	6,721,585	B1	4/2004	Parker
6,571,114	B1	5/2003	Koike et al.	6,725,074	B1	4/2004	Kästle
6,574,491	B2	6/2003	Elghazzawi	6,725,075	B2	4/2004	Al-Ali
6,580,086	B1	6/2003	Schulz et al.	6,731,963	B2	5/2004	Finarov et al.
6,584,336	B1	6/2003	Ali et al.	6,731,967	B1	5/2004	Turcott
6,587,703	B2	7/2003	Cheng et al.	6,735,459	B2	5/2004	Parker
6,587,704	B1	7/2003	Fine et al.	6,745,060	B2	6/2004	Diab et al.
6,589,172	B2	7/2003	Williams et al.	6,745,061	B1	6/2004	Hicks et al.
6,591,122	B2	7/2003	Schmitt	6,748,253	B2	6/2004	Norris et al.
6,591,123	B2	7/2003	Fein et al.	6,748,254	B2	6/2004	O'Neill et al.
6,594,511	B2	7/2003	Stone et al.	6,754,515	B1	6/2004	Pologe
6,594,512	B2	7/2003	Huang	6,754,516	B2	6/2004	Mannheimer
6,594,513	B1	7/2003	Jobsis et al.	6,760,607	B2	7/2004	Al-Ali
6,597,931	B1	7/2003	Cheng et al.	6,760,609	B2	7/2004	Jacques
6,597,933	B2	7/2003	Kiani et al.	6,760,610	B2	7/2004	Tschupp et al.
6,600,940	B1	7/2003	Fein et al.	6,763,255	B2	7/2004	DeLonzor et al.
6,606,509	B2	8/2003	Schmitt	6,763,256	B2	7/2004	Kimball et al.
6,606,510	B2	8/2003	Swedlow et al.	6,770,028	B1	8/2004	Ali et al.
6,606,511	B1	8/2003	Ali et al.	6,771,994	B2	8/2004	Kiani et al.

6,773,397	B2	8/2004	Kelly	7,039,449	B2	5/2006	Al-Ali
6,778,923	B2	8/2004	Norris et al.	7,043,289	B2	5/2006	Fine et al.
6,780,158	B2	8/2004	Yarita	7,047,055	B2	5/2006	Boas et al.
6,791,689	B1	9/2004	Weckström	7,047,056	B2	5/2006	Hannula et al.
6,792,300	B1	9/2004	Diab et al.	7,060,035	B2	6/2006	Wasserman
6,793,654	B2	9/2004	Lemberg	7,062,307	B2	6/2006	Norris et al.
6,801,797	B2	10/2004	Mannheimer et al.	7,067,893	B2	6/2006	Mills et al.
6,801,798	B2	10/2004	Geddes et al.	7,072,701	B2	7/2006	Chen et al.
6,801,799	B2	10/2004	Mendelson	7,072,702	B2	7/2006	Edgar, Jr. et al.
6,801,802	B2	10/2004	Sitzman et al.	7,079,880	B2	7/2006	Stetson
6,802,812	B1	10/2004	Walker et al.	7,085,597	B2	8/2006	Fein et al.
6,805,673	B2	10/2004	Dekker	7,096,052	B2	8/2006	Mason et al.
6,810,277	B2	10/2004	Edgar, Jr. et al.	7,096,054	B2	8/2006	Abdul-Hafiz et al.
6,813,511	B2	11/2004	Diab et al.	7,107,088	B2	9/2006	Aceti
6,816,741	B2	11/2004	Diab	7,113,815	B2	9/2006	O'Neil et al.
6,819,950	B2	11/2004	Mills	7,123,950	B2	10/2006	Mannheimer
6,822,564	B2	11/2004	Al-Ali	7,127,278	B2	10/2006	Melker et al.
6,825,619	B2	11/2004	Norris	7,130,671	B2	10/2006	Baker, Jr. et al.
6,826,419	B2	11/2004	Diab et al.	7,132,641	B2	11/2006	Schulz et al.
6,829,496	B2	12/2004	Nagai et al.	7,133,711	B2	11/2006	Chernoguz et al.
6,830,711	B2	12/2004	Mills et al.	7,139,599	B2	11/2006	Terry
6,836,679	B2	12/2004	Baker, Jr. et al.	7,142,142	B2	11/2006	Petersen et al.
6,839,579	B1	1/2005	Chin	7,142,901	B2	11/2006	Kiani et al.
6,839,580	B2	1/2005	Zonios et al.	7,162,288	B2	1/2007	Nordstrom
6,839,582	B2	1/2005	Heckel	7,162,306	B2	1/2007	Caby et al.
6,839,659	B2	1/2005	Tarassenko et al.	7,184,809	B1	2/2007	Sterling et al.
6,842,635	B1	1/2005	Parker	7,190,987	B2	3/2007	Lindekugel et al.
6,845,256	B2	1/2005	Chin et al.	7,198,778	B2	4/2007	Mannheimer et al.
6,850,053	B2	2/2005	Daalmans et al.	7,209,775	B2	4/2007	Bae et al.
6,850,787	B2	2/2005	Weber et al.	7,215,984	B2	5/2007	Diab et al.
6,850,788	B2	2/2005	Al-Ali	7,225,006	B2	5/2007	Al-Ali et al.
6,850,789	B2	2/2005	Schweitzer, Jr. et al.	7,236,811	B2	6/2007	Schmitt
6,861,639	B2	3/2005	Al-Ali	7,239,905	B2	7/2007	Kiani-Azarbayjany et al.
6,863,652	B2	3/2005	Huang et al.	7,248,910	B2	7/2007	Li et al.
6,865,407	B2	3/2005	Kimball et al.	7,251,518	B2	7/2007	Herrmann
6,873,865	B2	3/2005	Steuer et al.	7,254,433	B2	8/2007	Diab et al.
6,879,850	B2	4/2005	Kimball	7,254,434	B2	8/2007	Schulz et al.
6,882,874	B2	4/2005	Huiku	7,263,395	B2	8/2007	Chan et al.
6,889,153	B2	5/2005	Dietiker	7,272,426	B2	9/2007	Schmid
6,898,451	B2	5/2005	Wuori	7,280,858	B2	10/2007	Al-Ali et al.
6,898,452	B2	5/2005	Al-Ali et al.	7,295,866	B2	11/2007	Al-Ali et al.
6,909,912	B2	6/2005	Melker et al.	7,302,284	B2	11/2007	Baker, Jr. et al.
6,912,413	B2	6/2005	Rantala et al.	7,305,262	B2	12/2007	Brodnick et al.
6,916,289	B2	7/2005	Schnall	7,315,753	B2	1/2008	Baker, Jr. et al.
6,920,345	B2	7/2005	Al-Ali et al.	7,336,983	B2	2/2008	Baker, Jr. et al.
6,931,268	B1	8/2005	Kiani-Azarbayjany et al.	7,355,539	B2	4/2008	Petersen et al.
6,931,269	B2	8/2005	Terry	7,373,193	B2	5/2008	Al-Ali et al.
6,934,570	B2	8/2005	Kiani et al.	7,477,571	B2	1/2009	Melese et al.
6,939,307	B1	9/2005	Dunlop	2001/0005773	A1	6/2001	Larsen et al.
6,941,162	B2	9/2005	Fudge et al.	2001/0020122	A1	9/2001	Steuer et al.
6,947,780	B2	9/2005	Scharf	2001/0021803	A1	9/2001	Blank et al.
6,947,781	B2	9/2005	Asada et al.	2001/0039376	A1	11/2001	Steuer et al.
6,950,687	B2	9/2005	Al-Ali	2001/0044700	A1	11/2001	Kobayashi et al.
6,961,598	B2	11/2005	Diab	2001/0051767	A1	12/2001	Williams et al.
6,963,767	B2	11/2005	Rantala et al.	2002/0026106	A1	2/2002	Khalil et al.
6,971,580	B2	12/2005	DeLonzor et al.	2002/0026109	A1	2/2002	Diab et al.
6,983,178	B2	1/2006	Fine et al.	2002/0028990	A1	3/2002	Shepherd et al.
6,985,763	B2	1/2006	Boas et al.	2002/0035318	A1	3/2002	Mannheimer et al.
6,985,764	B2	1/2006	Mason et al.	2002/0038078	A1	3/2002	Ito
6,990,426	B2	1/2006	Yoon et al.	2002/0038079	A1	3/2002	Steuer et al.
6,992,751	B2	1/2006	Al-Ali	2002/0042558	A1	4/2002	Mendelson
6,992,772	B2	1/2006	Block et al.	2002/0049389	A1	4/2002	Abreu
6,993,371	B2	1/2006	Kiani et al.	2002/0062071	A1	5/2002	Diab et al.
6,993,372	B2	1/2006	Fine et al.	2002/0068859	A1	6/2002	Knopp
6,996,427	B2	2/2006	Ali et al.	2002/0111748	A1	8/2002	Kobayashi et al.
7,003,338	B2	2/2006	Weber et al.	2002/0128544	A1	9/2002	Diab et al.
7,003,339	B2	2/2006	Diab et al.	2002/0133067	A1	9/2002	Jackson, III
7,006,855	B1	2/2006	Sarussi	2002/0133068	A1	9/2002	Huiku
7,006,856	B2	2/2006	Baker, Jr. et al.	2002/0156354	A1	10/2002	Larson
7,010,341	B2	3/2006	Chance	2002/0161287	A1	10/2002	Schmitt
7,016,715	B2	3/2006	Stetson	2002/0161290	A1	10/2002	Chance
7,020,507	B2	3/2006	Scharf et al.	2002/0165439	A1	11/2002	Schmitt
7,024,233	B2	4/2006	Ali et al.	2002/0173706	A1	11/2002	Takatani
7,024,235	B2	4/2006	Melker et al.	2002/0173709	A1	11/2002	Fine et al.
7,025,728	B2	4/2006	Ito et al.	2002/0190863	A1	12/2002	Lynn
7,027,849	B2	4/2006	Al-Ali et al.	2002/0198442	A1	12/2002	Rantala et al.
7,027,850	B2	4/2006	Wasserman	2002/0198443	A1	12/2002	Ting
7,030,749	B2	4/2006	Al-Ali	2003/0018243	A1	1/2003	Gerhardt et al.
7,035,697	B1	4/2006	Brown	2003/0023140	A1	1/2003	Chance

Page 7

2003/0036690	A1	2/2003	Geddes et al.	2004/0230108	A1	11/2004	Melker et al.
2003/0045785	A1	3/2003	Diab et al.	2004/0236196	A1	11/2004	Diab et al.
2003/0055324	A1	3/2003	Wasserman	2004/0242980	A1	12/2004	Kiani et al.
2003/0060693	A1	3/2003	Monfire et al.	2004/0249252	A1	12/2004	Fine et al.
2003/0073889	A1	4/2003	Keilbach et al.	2004/0257557	A1	12/2004	Block et al.
2003/0073890	A1	4/2003	Hanna	2004/0260161	A1	12/2004	Melker et al.
2003/0100840	A1	5/2003	Sugiura et al.	2004/0267103	A1	12/2004	Li et al.
2003/0132495	A1	7/2003	Mills et al.	2004/0267104	A1	12/2004	Hannula et al.
2003/0135099	A1	7/2003	Al-Ali	2004/0267140	A1	12/2004	Ito et al.
2003/0139687	A1	7/2003	Abreu	2005/0004479	A1	1/2005	Townsend et al.
2003/0144584	A1	7/2003	Mendelson	2005/0010092	A1	1/2005	Weber et al.
2003/0162414	A1	8/2003	Schulz et al.	2005/0020887	A1	1/2005	Goldberg
2003/0171662	A1	9/2003	O'Connor et al.	2005/0020894	A1	1/2005	Norris et al.
2003/0176776	A1	9/2003	Huiku	2005/0033128	A1	2/2005	Ali et al.
2003/0181799	A1	9/2003	Lindekugel et al.	2005/0033129	A1	2/2005	Edgar, Jr. et al.
2003/0187337	A1	10/2003	Tarassenko et al.	2005/0043599	A1	2/2005	O'Mara
2003/0195402	A1	10/2003	Fein et al.	2005/0043600	A1	2/2005	Diab et al.
2003/0197679	A1	10/2003	Ali et al.	2005/0049470	A1	3/2005	Terry
2003/0212316	A1	11/2003	Leiden et al.	2005/0049471	A1	3/2005	Aceti
2003/0220548	A1	11/2003	Schmitt	2005/0075550	A1	4/2005	Lindekugel
2003/0220576	A1	11/2003	Diab	2005/0080323	A1	4/2005	Kato
2003/0225323	A1	12/2003	Kiani et al.	2005/0101850	A1	5/2005	Parker
2003/0225337	A1	12/2003	Scharf et al.	2005/0113651	A1	5/2005	Wood et al.
2003/0236452	A1	12/2003	Melker et al.	2005/0113656	A1	5/2005	Chance
2003/0236647	A1	12/2003	Yoon et al.	2005/0168722	A1	8/2005	Forstner et al.
2004/0006261	A1	1/2004	Swedlow et al.	2005/0177034	A1	8/2005	Beaumont
2004/0010188	A1	1/2004	Wasserman	2005/0192488	A1	9/2005	Bryenton
2004/0024297	A1	2/2004	Chen et al.	2005/0197548	A1	9/2005	Dietiker
2004/0024326	A1	2/2004	Yeo et al.	2005/0203357	A1	9/2005	Debreczeny
2004/0034293	A1	2/2004	Kimball	2005/0228248	A1	10/2005	Dietiker
2004/0039272	A1	2/2004	Abdul-Hafiz et al.	2005/0267346	A1	12/2005	Faber et al.
2004/0039273	A1	2/2004	Terry	2005/0277819	A1	12/2005	Kiani et al.
2004/0054269	A1	3/2004	Rantala et al.	2005/0283059	A1	12/2005	Iyer et al.
2004/0054291	A1	3/2004	Schulz et al.	2006/0009688	A1	1/2006	Lamego et al.
2004/0059209	A1	3/2004	Al-Ali et al.	2006/0015021	A1	1/2006	Cheng
2004/0059210	A1	3/2004	Stetson	2006/0020181	A1	1/2006	Schmitt
2004/0064020	A1	4/2004	Diab et al.	2006/0030763	A1	2/2006	Mannheimer et al.
2004/0068164	A1	4/2004	Diab et al.	2006/0052680	A1	3/2006	Diab
2004/0087846	A1	5/2004	Wasserman	2006/0058594	A1	3/2006	Ishizuka et al.
2004/0092805	A1	5/2004	Yarita	2006/0058683	A1	3/2006	Chance
2004/0097797	A1	5/2004	Porges et al.	2006/0064024	A1	3/2006	Schnall
2004/0098009	A1	5/2004	Boecker et al.	2006/0084852	A1	4/2006	Mason et al.
2004/0107065	A1	6/2004	Al-Ali et al.	2006/0089547	A1	4/2006	Sarussi
2004/0116788	A1	6/2004	Chernoguz et al.	2006/0106294	A1	5/2006	Maser et al.
2004/0116789	A1	6/2004	Boaz et al.	2006/0195028	A1	8/2006	Hannula et al.
2004/0117891	A1	6/2004	Hannula et al.	2006/0224053	A1	10/2006	Black et al.
2004/0122300	A1	6/2004	Boas et al.	2006/0224058	A1	10/2006	Mannheimer
2004/0122302	A1	6/2004	Mason et al.	2006/0247501	A1	11/2006	Ali
2004/0127779	A1	7/2004	Steuer et al.	2006/0253007	A1	11/2006	Cheng et al.
2004/0133087	A1	7/2004	Ali et al.	2006/0258921	A1	11/2006	Addison et al.
2004/0133088	A1	7/2004	Al-Ali et al.	2006/0276700	A1	12/2006	O'Neil
2004/0138538	A1	7/2004	Stetson	2007/0032710	A1	2/2007	Raridan et al.
2004/0138540	A1	7/2004	Baker, Jr. et al.	2007/0032712	A1	2/2007	Raridan et al.
2004/0143172	A1	7/2004	Fudge et al.	2007/0032715	A1	2/2007	Eghbal et al.
2004/0147821	A1	7/2004	Al-Ali et al.	2007/0049811	A1	3/2007	Kobayashi et al.
2004/0147822	A1	7/2004	Al-Ali et al.	2007/0073121	A1	3/2007	Hoarau et al.
2004/0147823	A1	7/2004	Kiani et al.	2007/0073125	A1	3/2007	Hoarau et al.
2004/0147824	A1	7/2004	Diab et al.	2007/0073126	A1	3/2007	Raridan, Jr.
2004/0152965	A1	8/2004	Diab et al.	2007/0073128	A1	3/2007	Hoarau et al.
2004/0158134	A1	8/2004	Diab et al.	2007/0260132	A1	11/2007	Sterling
2004/0158135	A1	8/2004	Baker, Jr. et al.	2008/0117616	A1	5/2008	Coakley
2004/0162472	A1	8/2004	Berson et al.	2009/0171175	A1	7/2009	Li et al.
2004/0171920	A1	9/2004	Mannheimer et al.				
2004/0171948	A1	9/2004	Terry				
2004/0176670	A1	9/2004	Takamura et al.				
2004/0176671	A1	9/2004	Fine et al.	DE	19647877	5/1998	
2004/0181133	A1	9/2004	Al-Ali	EP	0615723	9/1994	
2004/0181134	A1	9/2004	Baker, Jr. et al.	EP	0702931	3/1996	
2004/0186358	A1	9/2004	Chernow et al.	EP	0724860	8/1996	
2004/0199063	A1	10/2004	O'Neil et al.	EP	1332713	8/2003	
2004/0204636	A1	10/2004	Diab et al.	EP	1491135	12/2004	
2004/0204637	A1	10/2004	Diab et al.	FR	2685865	7/1993	
2004/0204638	A1	10/2004	Diab et al.	JP	63275325	11/1988	
2004/0204639	A1	10/2004	Casciani et al.	JP	3124073	5/1991	
2004/0204865	A1	10/2004	Lee et al.	JP	3170866	7/1991	
2004/0210146	A1	10/2004	Diab et al.	JP	3238813	10/1991	
2004/0215069	A1	10/2004	Mannheimer	JP	3245042	10/1991	
2004/0230106	A1	11/2004	Schmitt et al.	JP	4332536	11/1992	
2004/0230107	A1	11/2004	Asada et al.	JP	5049624	3/1993	
				JP	6154177	6/1994	
FOREIGN PATENT DOCUMENTS							

JP	6269430	9/1994
JP	6285048	10/1994
JP	7001273	1/1995
JP	7124138	5/1995
JP	7136150	5/1995
JP	2003194714	7/2003
JP	2003210438	7/2003
JP	2004194908	7/2004
JP	2004248819	9/2004
JP	2004261364	9/2004
JP	2004290545	10/2004
JP	2005034472	2/2005
WO	WO8909566	10/1989
WO	WO9001293	2/1990
WO	WO9101678	2/1991
WO	WO9111137	8/1991
WO	WO9200513	1/1992
WO	WO9309711	5/1993
WO	WO9316629	9/1993
WO	WO9423643	10/1994
WO	WO9502358	1/1995
WO	WO9639927	12/1996
WO	WO9932030	7/1999
WO	WO0021438	4/2000
WO	WO0028888	5/2000
WO	WO0140776	6/2001
WO	WO0176461	10/2001
WO	WO0176471	10/2001
WO	WO03039326	5/2003
WO	WO2005065540	7/2005
WO	WO2008039195	4/2008

OTHER PUBLICATIONS

- Barnum, P.T., et al.; "Novel Pulse Oximetry Technology Capable of Reliable Bradycardia Monitoring in the Neonate," *Respiratory Care*, vol. 42, No. 1, p. 1072 (Nov. 1997).
- Barreto, Armando B., et al.; "Adaptive LMS Delay Measurement in dual Blood Volume Pulse Signals for Non-Invasive Monitoring," *IEEE*, pp. 117-120 (1997).
- Buschman, J.P., et al.; "Principles and Problems of Calibration of Fetal Oximeters," *Biomedizinische Technik*, vol. 42, pp. 265-266 (1997).
- Leahy, Martin J., et al.; "Sensor Validation in Biomedical Applications," *IFAC Modelling and Control in Biomedical Systems*, Warwick, UK; pp. 221-226 (1997).
- Pickett, John, et al.; "Pulse Oximetry and PPG Measurements in Plastic Surgery," *Proceedings—19th International Conference—IEEE/EMBS*, Chicago, Illinois, Oct. 30-Nov. 2, 1997, pp. 2330-2332.
- East, Christine E., et al.; "Fetal Oxygen Saturation and Uterine Contractions During Labor," *American Journal of Perinatology*, vol. 15, No. 6, pp. 345-349 (Jun. 1998).
- Edrich, Thomas, et al.; "Can the Blood Content of the Tissues be Determined Optically During Pulse Oximetry Without Knowledge of the Oxygen Saturation?—An In-Vitro Investigation," *Proceedings of the 20th Annual International conference of the IEEE Engie in Medicine and Biology Society*, vol. 20, No. 6, p. 3072-3075, 1998.
- Such, Hans Olaf; "Optoelectronic Non-invasive Vascular Diagnostics Using multiple Wavelength and Imaging Approach," *Dissertation*, (1998).
- Lutter, N., et al.; "Comparison of Different Evaluation Methods for a Multi-wavelength Pulse Oximeter," *Biomedizinische Technik*, vol. 43, (1998).
- Ikeda, Kenji, et al.; "Improvement of Photo-Electric Plethysmograph Applying Newly Developed Opto-Electronic Devices," *IEEE Tencon*, pp. 1109-1112 (1999).
- Todd, Bryan, et al.; "The Identification of Peaks in Physiological Signals," *Computers and Biomedical Research*, vol. 32, pp. 322-335 (1999).
- Seelbach-Göbel, Birgit, et al.; "The prediction of fetal acidosis by means of intrapartum fetal pulse oximetry," *Am J. Obstet. Gynecol.*, vol. 180, No. 1, Part 1, pp. 73-81 (1999).
- Goldman, Julian M.; "Masimo Signal Extraction Pulse Oximetry," *Journal of Clinical Monitoring and Computing*, vol. 16, pp. 475-483 (2000).
- Coetzee, Frans M.; "Noise-Resistant Pulse Oximetry Using a Synthetic Reference Signal," *IEEE Transactions on Biomedical Engineering*, vol. 47, No. 8, Aug. 2000, pp. 1018-1026.
- Nilsson, Lena, et al.; "Monitoring of Respiratory Rate in Postoperative Care Using a New Photoplethysmographic Technique," *Journal of Clinical Monitoring and Computing*, vol. 16, pp. 309-315 (2000).
- Kaestle, S.; "Determining Artefact Sensitivity of New Pulse Oximeters in Laboratory Using Signals Obtained from Patient," *Biomedizinische Technik*, vol. 45 (2000).
- Belal, Suliman Yousef, et al.; "A fuzzy system for detecting distorted plethysmogram pulses in neonates and paediatric patients," *Physiol. Meas.*, vol. 22, pp. 397-412 (2001).
- Cubeddu, Rinaldo, et al.; "Portable 8-channel time-resolved optical imager for functional studies of biological tissues," *Photon Migration, Optical Coherence Tomography, and Microscopy, Proceedings of SPIE*, vol. 4431, pp. 260-265 (2001).
- Cysewska-Sobusaik, Anna; "Metrological Problems With noninvasive Transillumination of Living Tissues," *Proceedings of SPIE*, vol. 4515, pp. 15-24 (2001).
- Lopez-Silva, Sonia Maria Lopez, et al.; "NIR transmittance pulse oximetry system with laser diodes," *Clinical Diagnostic Systems, Proceedings of SPIE*, vol. 4255, pp. 80-87 (2001).
- Malettras, Francois-Xavier, et al.; "Construction and calibration of a new design of Fiber Optic Respiratory Plethysmograph (FORP)," *Optomechanical Design and Engineering, Proceedings of SPIE*, vol. 4444, pp. 285-293 (2001).
- Earthrowl-Gould, T., et al.; "Chest and abdominal surface motion measurement for continuous monitoring of respiratory function," *Proc. Instn Mech Engrs*, V215, Part H; pp. 515-520 (2001).
- Relente, A.R., et al.; "Characterization and Adaptive Filtering of Motion Artifacts in Pulse Oximetry using Accelerometers," *Proceedings of the Second joint EMBS/BMES Conference*, Houston, Texas, Oct. 23-26, 2002; pp. 1769-1770.
- Liu, Ying, et al.; "Sensor design of new type reflectance pulse oximetry," *Optics in Health Care and Biomedical Optics: Diagnostics and Treatment, Proceedings of SPIE*, vol. 4916, pp. 98-102 (2002).
- Chan, K.W., et al.; "17.3: Adaptive Reduction of Motion Artifact from Photoplethysmographic Recordings using a Variable Step-Size LMS Filter," *IEEE*, pp. 1343-1346 (2002).
- Yao, Jianchu, et al.; "Design of a Plug-and-Play Pulse Oximeter," *Proceedings of the Second Joint EMBS/BMES Conference*, Houston, Texas, Oct. 23-26, 2002; pp. 1752-1753.
- Yoon, Gilwon, et al.; "Multiple diagnosis based on Photoplethysmography: hematocrit, SpO₂, pulse and respiration," *Optics in Health Care and Biomedical optics: Diagnostics and Treatment; Proceedings of the SPIE*, vol. 4916; pp. 185-188 (2002).
- Lopez-Silva, Sonia Maria Lopez, et al.; "Near-infrared transmittance pulse oximetry with laser diodes," *Journal of Biomedical Optics*, vol. 8, No. 3, pp. 525-533 (Jul. 2003).
- Cyrrill, D., et al.; "Adaptive Comb Filter for Quasi-Periodic Physiologic Signals," *Proceedings of the 25th Annual International Conference of the IEEE EMBS*, Cancun, Mexico, Sep. 17-21, 2003; pp. 2439-2442.
- Matthews, Nora S. et al.; "An evaluation of pulse oximeters in dogs, cats and horses," *Veterinary Anaesthesia and Analgesia*, vol. 30, pp. 3-14 (2003).
- Stetson, Paul F.; "Determining Heart Rate from Noisy Pulse Oximeter Signals Using Fuzzy Logic," *The IEEE International Conference on Fuzzy Systems*, St. Louis, Missouri, May 25-28, 2003; pp. 1053-1058.
- Pujary, C., et al.; "Photodetector Size Considerations in the Design of a Noninvasive Reflectance Pulse Oximeter for Telemedicine Applications," *IEEE*, pp. 148-149 (2003).
- Lee, C.M., et al.; "Reduction of motion artifacts from photoplethysmographic recordings using wavelet denoising approach," *IEEE EMBS Asian-Pacific Conference on Biomedical Engineering*, Oct. 20-22, 2003; pp. 194-195.

Johnston, W.S., et al.; "Extracting Breathing Rate Information from a Wearable Reflectance Pulse Oximeter Sensor," *Proceedings of the 26th Annual International conference of the IEEE EMBS*, San Francisco, California; Sep. 1-5, 2004; pp. 5388-5391.

Spigulis, Janis, et al.; "Optical multi-channel sensing of skin blood pulsations," *Optical Sensing, Proceedings of SPIE*, vol. 5459, pp. 46-53 (2004).

Lutter, N., et al.; "Accuracy of Noninvasive Continuous Blood Pressure; Measurement Utilising the Pulse Transit Time," *Journal of clinical Monitoring and Computing*, vol. 17, Nos. 7-8, pp. 469 (2002).

A. Johansson; "Neural network for photoplethysmographic respiratory rate monitoring," *Medical & Biological Engineering & Computing*, vol. 41, pp. 242-248 (2003).

Lopez-Silva, S.M., et al.; "Transmittance Photoplethysmography and Pulse Oximetry With Near Infrared Laser Diodes," *IMTC 2004—Instrumentation and Measurement Technology Conference*, Como, Italy, May 18-20, 2004; pp. 718-723.

Addison, Paul S., et al.; "A novel time-frequency-based 3D Lissajous figure method and its application to the determination of oxygen saturation from the photoplethysmogram," *Institute of Physics Publishing, Meas. Sci. Technol.*, vol. 15, pp. L15-L18 (2004).




FIG. 1




FIG. 2




FIG. 3






FIG. 4






FIG. 5C




FIG. 6

METHOD AND APPARATUS FOR DETECTING AND ANALYZING VARIATIONS IN A PHYSIOLOGIC PARAMETER

BACKGROUND

The present disclosure relates generally to identifying and/or analyzing variations in a measured physiologic parameter, such as blood oxygen saturation (SpO_2) measured using pulse oximetry. More particularly, the present disclosure includes embodiments directed to analyzing variations in SpO_2 values and/or variations in SpO_2 trend data that are smaller in magnitude than the accuracy, display precision, and/or calibration of the measurement.

This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present disclosure, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present disclosure. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.

Pulse oximetry is used to continuously monitor the oxygen content of patients' blood in various settings (e.g., operating rooms, delivery rooms, and so forth). Specifically, pulse oximetry uses light waves to indirectly measure the arterial blood oxygen saturation of patients. For example, in operation, conventional two wavelength pulse oximeters emit light from two emitters (e.g., light emitting diodes (LEDs)) into a pulsatile tissue bed and collect the transmitted light with a detector (e.g., a photodiode). The detected light may then be utilized to estimate a level of oxygen saturation in the blood that is present in the tissue bed. The emitters and detector may be positioned in various orientations for different types of pulse oximetry. For example, in transmission pulse oximetry, the emitters and detector are positioned substantially opposite one another (e.g., on opposite sides of a patient's finger), while in reflectance pulse oximetry, the emitters and detector are placed adjacent to one another. The emitters and detector are typically housed in a sensor which connects to pulse oximeter electronics.

The "pulse" in pulse oximetry comes from the time varying amount of arterial blood in the tissue bed during the cardiac cycle. The processed signals from the photodetector create the familiar plethysmographic waveform due to the cycling light attenuation caused by the varying amount of arterial blood that the light from the emitters passes through. With regard to conventional two-wavelength pulse oximeters, at least one of two LEDs emits light at a wavelength at some point in the electromagnetic spectrum where the absorption of oxyhemoglobin (O_2Hb) differs from the absorption of reduced hemoglobin (HHb), and the other of the two LEDs emits light at a wavelength that is at a different point in the spectrum where the absorption differences between HHb and O_2Hb are different from those at the first wavelength. The use of these differing wavelengths facilitates estimation of blood oxygen saturation.

Typically, pulse oximeters utilize one wavelength in the red part of the visible spectrum near 660 nanometers (nm), and one in the near infrared part of the spectrum in the range of 880 nm-940 nm. Photocurrents generated within the detector are detected and processed for measuring the modulation ratio of the red to infrared signals. This modulation ratio has been observed to correlate well to arterial oxygen saturation. Pulse oximeters and pulse oximetry sensors are empirically calibrated by measuring the modulation ratio over a range of in vivo measured arterial oxygen saturations (SaO_2) on a set

of patients, healthy volunteers, or animals. The observed correlation is used in an inverse manner to determine SpO_2 based on the real-time measured value of modulation ratios. It should be noted that, as used herein, SaO_2 refers to the in vivo measured functional saturation, while SpO_2 refers to the estimated functional saturation using pulse oximetry.

Traditional uses of pulse oximetry are based on rounded values of SpO_2 . Indeed, because SpO_2 values are generally only accurate to about 1 or 2%, the SpO_2 values are typically used after they have been rounded to the nearest 1%. Further, traditional uses of pulse oximetry may not typically benefit from more precise calculation. For example, pulse oximetry has traditionally been used on patient populations where arterial blood oxygen saturation is generally greater than 90%. In other words, pulse oximetry has traditionally been used in patient populations, wherein the functional hemoglobin in the arterial blood includes at least 90% oxyhemoglobin and 10% or less reduced hemoglobin. In such patient populations, oxygen saturation seldom falls below 80%, and such low values are generally indicative of an unhealthy condition that warrants intervention. Thus, in this and similar situations where pulse oximetry has typically been employed, a high degree of precision in the estimate of blood oxygen saturation based on traditional pulse oximetry has not generally been considered to be clinically relevant.

BRIEF DESCRIPTION OF THE DRAWINGS

Advantages of the present disclosure may become apparent upon reading the following detailed description and upon reference to the drawings in which:

FIG. 1 is a perspective view of a pulse oximeter system in accordance with an embodiment;

FIG. 2 is a block diagram of a pulse oximeter system in accordance with an embodiment;

FIG. 3 is a block diagram of a physiologic parameter control system in accordance with an embodiment;

FIG. 4 is a perspective view of a sensor in accordance with an embodiment;

FIG. 5A, FIG. 5B, and FIG. 5C is a set of charts illustrating various variables plotted against wavelength to demonstrate optimization of sensor sensitivity in accordance with an embodiment; and

FIG. 6 is a chart illustrating modulation ratio plotted against blood oxygen saturation at different emitter-detector spacing to demonstrate sensor optimization in accordance with an embodiment.

DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

One or more specific embodiments of the present disclosure will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.

Present embodiments may be applied in the field of pulse oximetry. As indicated above, pulse oximetry may be defined

as a non-invasive technique that facilitates monitoring of a patient's blood characteristics. For example, pulse oximetry may be used to measure blood oxygen saturation of hemoglobin in a patient's arterial blood and/or the patient's heart rate. Specifically, these measurements may be acquired using a non-invasive sensor that passes light through a portion of a patient's tissue and photo-electrically senses the absorption and scattering of the light through the tissue. Typical pulse oximetry technology currently utilizes two LEDs and a single optical detector to measure pulse and oxygen saturation of a given tissue bed. Such measurements are largely based on absorption of emitted light by specific types of blood constituents. Once acquired, this measurement may be used with various algorithms to estimate a relative amount of blood constituent in the tissue. For example, such measurements may provide a ratio of oxygenated to the sum of oxygenated and deoxygenated hemoglobin (i.e., functional hemoglobin) in the volume being monitored.

An SpO₂ value is generally considered to be limited in accuracy to within a few percentage points relative to invasively measured values of SaO₂. Thus, traditional pulse oximeters do not typically display SpO₂ values that have a greater precision than one percent. Likewise, traditional pulse oximeter systems do not perform control functions based on such precise values. It should be noted that the term "accurate" generally refers to a degree of correctness (i.e., closeness to a true value), while the term "precise" generally refers to a degree of exactness, that is, to the smallest change that can be detected in a value.

It has now been recognized that trending accuracy of high precision SpO₂ values is substantially more accurate than the individual values of SpO₂. In other words, the changes or differences between calculated SpO₂ values have been found to correspond closely with corresponding changes in values of SaO₂. Thus, changes in SpO₂ at high levels of precision are now recognized as accurate representations of changes in SaO₂. Accordingly, present embodiments are directed to systems and methods for analyzing variations in a measured physiologic parameter, such as SpO₂, where the variations are smaller in magnitude than the measurement's accuracy or display precision, or where the measurements are outside the displayed or calibrated range of the measured physiologic parameter. For example, SpO₂ values may only be accurate to within a range of +/-1 or 2% relative to an actual value of SaO₂. However, in present embodiments, SpO₂ values may be determined at a high resolution (e.g., a precision of 0.1%, 0.01%, or 0.001%) for use in pattern detection calculations, control algorithms, and so forth. Indeed, present embodiments may not round to the nearest 1%, which may increase the accuracy in detected changes in SpO₂. Similarly, while a pulse oximeter may only display SpO₂ values with limited precision (e.g., only whole number percentage values) and/or SpO₂ values within the range of 0-100%, present embodiments may utilize high resolution SpO₂ values and SpO₂ values outside the range of 0-100% to facilitate analysis, control, and treatment based on subtle changes in the high resolution SpO₂ values over time.

Specifically, present embodiments may utilize subtle variations in high resolution SpO₂ values, such as an incremental variation in the tenths, hundredths, or thousandths digit of an SpO₂ value, to detect or compensate for more significant variations in a related physiologic parameter. For example, small changes in an SpO₂ value may correspond to significant changes in minute ventilation, respiration rate, apnea, partial pressure of oxygen in the arterial blood and so forth. Thus, in accordance with present embodiments, subtle changes in high resolution SpO₂ values detected over time may be uti-

lized to analyze and/or control variations in minute ventilation, respiration rate, partial pressure of oxygen in the arterial blood and/or apnea (e.g., obstructive sleep apnea or central sleep apnea). Further, present embodiments may include features for tracking subtle changes in SpO₂ and presenting them as changes in a related parameter based on the use of the SpO₂ values as a surrogate.

Further, present embodiments may facilitate detection, analysis, and/or control of physiologic parameters based on high resolution SpO₂ values by utilizing and/or including a sensor that is capable of enhancing measurement precision. For example, present embodiments may include an SpO₂ sensor with an emitter that functions to emit light at one or more wavelengths that facilitate increased sensitivity. Such sensitivity may further enable detection of high precision changes in SpO₂ values by a processor of the sensor, which can be utilized for control, detection, and so forth in accordance with present embodiments. It is now recognized based on calculations directed to increasing the slope of a modulation ratio versus SaO₂ curve, that the relative change or percentage difference in HHb to O₂Hb of a pair of signals facilitates high resolution determination of SpO₂ values. Specifically, for example, an SpO₂ sensor in accordance with present embodiments may include emitters with wavelengths near 660 nm (e.g., 650-670 nm) and near 950 nm (e.g., 940-1000 nm), as these two wavelengths may exhibit the greatest relative differences in absorbance from HHb and O₂Hb and, as a result, provide improved SpO₂ precision. It may be desirable to use a wavelength of 950 nm because silicon detectors generally roll off after around 950 nm. In some embodiments, green or yellow light may be utilized separately or in combination with the sensor's others LEDs. For example, a green LED that produces light with a wavelength in a range of about 500-570 nm or a yellow LED that produces light with a wavelength in a range of about 570-600 nm may be utilized in accordance with present embodiments because the wavelengths are typically more highly absorbed by hemoglobin, and may therefore enable the acquisition of a stronger pulsatile signal that facilitates detection of smaller changes in SpO₂.

Additionally, the spacing used between the emitter and detector in a reflectance sensor may be chosen to increase the precision of SpO₂ calculations. With a narrow spacing between the emitter and detector, the change in the pulse oximeter's modulation ratio for a given change in SaO₂ is larger than is found with a less narrow spacing. For example, a sensor with a 2-mm spacing between the LED light sources and the photodetector provides an improved precision in the SpO₂ estimate of SaO₂ relative to a sensor with a 10-mm spacing. Accordingly, present embodiments may utilize a spacing of approximately 2-3 mm between the LED light sources to generate high resolution values.

FIG. 1 illustrates a perspective view of a pulse oximetry system **10** in accordance with present embodiments. The system **10** may be utilized to observe the blood constituents of a patient's arterial blood to facilitate estimation of the state of oxygen exchange in the patient's body by emitting waves into tissue and detecting the waves after dispersion and/or reflection by the tissue. The system **10** may include a pulse oximeter or monitor **12** that communicatively couples to a sensor **14**. The monitor **12** may include a display **16**, a memory, a processor, and various monitoring and control features. The monitor **12** may be configured to perform pulse oximetry measurements, calculations, and control algorithms using high precision values in accordance with present embodiments. Further, the monitor **12** may be configured to display high resolution SpO₂ values based on the measurements, cal-

culations, and control algorithms. The sensor **14** may include a sensor cable **18**, a connector plug **20**, and a sensor assembly or body **22** configured to attach to a patient (e.g., a patient's finger, ear, forehead, or toe). Further, in the illustrated embodiment, the system **10** includes a separate display feature **24** that is communicatively coupled with the monitor **12** to facilitate presentation of pulse oximetry data and related data.

The sensor **14** includes an emitter **28** and a detector **30**. When attached to a patient's tissue and functioning, the emitter **28** transmits light at different wavelengths into the tissue and the detector **30** receives the light after it has passed through the tissue area. The amount of light that passes through the tissue and other characteristics of light waves may vary in accordance with the changing amount of certain blood constituents in the tissue and the related light absorption and/or scattering. For example, the system **10** may emit light from two or more LEDs **32**, or other suitable light sources such as lasers, into the pulsatile tissue and then detect the transmitted light with the detector **30**, such as a photodiode or photo-detector, after the light has passed through the pulsatile tissue. Such measurements may be utilized to estimate a percentage of blood oxygen saturation in the probed volume of blood. In other words, such measurements may be utilized to obtain an SpO₂ value. Further, such measurements may be utilized to track related parameters. For example, SpO₂ measurements may be utilized to track the partial pressure of oxygen (pO₂) in a patient's arterial blood by relating the pO₂ to the SpO₂ through the use of a selected or calculated oxygen dissociation curve. Indeed, SpO₂ may be utilized as a surrogate for pO₂.

FIG. 2 is a block diagram of an embodiment of the patient monitoring system **10** that may be configured to implement the techniques described herein. The system **10** may include the patient monitor **12** (e.g., a pulse oximeter) and the sensor **14**, which are configured to obtain and utilized high precision SpO₂ values. The sensor **14** is communicatively connected to the patient monitor **12** via a cable or wireless device. When the system **10** is operating, light from the emitter **28** may pass into a patient **100** and be scattered and detected by the detector **30**. The monitor **12** may include a microprocessor **102** connected to an internal bus **104**. Also connected to the bus **104** may be a RAM memory **106** and a display **108**. A time processing unit (TPU) **110** may provide timing control signals to light drive circuitry **112** which may control when the emitter **28** is illuminated, and if multiple light sources are used, the multiplexed timing for the different light sources. TPU **110** may also control the gating-in of signals from the detector **30** through an amplifier **116** and a switching circuit **118**. These signals may be sampled at the proper time, depending upon which of multiple light sources is illuminated, if multiple light sources are used. The received signal from the detector **30** may be passed through an amplifier **120**, a low pass filter **122**, and an analog-to-digital converter **124**. The digital data may then be stored in a queued serial module (QSM) **130**, for later downloading to the RAM **106** as the QSM **130** fills up. In one embodiment, there may be multiple parallel paths of separate amplifier, filter and A/D converters for multiple light wavelengths or spectra received. It should be noted that each of these features may be configured to facilitate the provision of SpO₂ values at a high level of precision in accordance with present embodiments. Present embodiments may be implemented on any suitable pulse oximeter, such as those available from Nellcor Puritan Bennett LLC.

In an embodiment, the sensor **14** may also contain an encoder **140** that provides signals indicative of the wave-

length of one or more light sources of the emitter **28** to allow the monitor **12** to select appropriate calibration coefficients for calculating a physiological parameter such as blood oxygen saturation. The encoder **140** may, for instance, be a coded resistor, EEPROM or other coding devices (such as a capacitor, inductor, PROM, RFID, a barcode, parallel resonant circuits, or a colorimetric indicator) that may provide a signal to the processor **102** related to the characteristics of the sensor **14** that may allow the processor **102** to determine the appropriate calibration characteristics for the sensor **14**. Further, the encoder **140** may include encryption coding that prevents a disposable part of the sensor **14** from being recognized by a processor **102** that is not able to decode the encryption. For example, a detector/decoder **144** may be required to translate information from the encoder **140** before it can be properly handled by the processor **102**. Present embodiments may be implemented on any suitable sensor, such as those available from Nellcor Puritan Bennett LLC.

In various embodiments, based at least in part upon the value of the received signals corresponding to the light received by detector **30**, the microprocessor **102** may calculate a physiological parameter using various algorithms. These algorithms may utilize coefficients, which may be empirically determined, corresponding to, for example, the wavelengths of light used. These may be stored in a ROM **144**. In a two-wavelength system, the particular set of coefficients chosen for any pair of wavelength spectra may be determined by the value indicated by the encoder **140** corresponding to a particular light source in a particular sensor **14**. For example, the first wavelength may be a wavelength that is highly sensitive to small quantities of deoxyhemoglobin in blood, and the second wavelength may be a complimentary wavelength. Specifically, for example, such wavelengths may be produced by orange, red, infrared, green, and/or yellow LEDs. Different wavelengths may be selected with control inputs **150**. The control inputs **150** may be, for instance, a switch on the monitor, a keyboard, or a port providing instructions from a remote host computer.

In various embodiments, the monitor **12** may be connected to a network via a network interface **152**. The network interface **152** may implement any networking technology or protocol, such as Ethernet, wireless Ethernet, and so forth. The network interface **152** may be connected to a network port **154** via a network cable or via a wireless connection. Additionally, the monitor **12** may include a non-volatile memory **160** that may store caregiver preferences, patient information, or any other information useful for configuring the monitor **12**. The software for performing the configuration of the monitor **12** and retrieval of information over the network interface **152** may also be stored on the memory **160**, or may be stored on the ROM **144**.

The components of the monitor **12** may be configured to detect store, and utilize SpO₂ values at high resolution. In other words, the monitor **12** may estimate SpO₂ values at precisions of 0.1%, 0.01%, 0.001%, and so forth. Additionally, the monitor **12** may perform calculations and control algorithms based on these high resolution values. Further, the monitor **12** may be configured to correlate subtle changes in the SpO₂ values to large change in related parameters, such as pO₂, based on an inherent relationship between the parameters.

Pulse oximetry values of SpO₂ are generally only accurate to +/-1 or 2% precision with respect to invasively measured values of SaO₂. Accordingly, traditional pulse oximeters generally display values that are rounded to the nearest 1%. Further, inherent accuracy limitations in pulse oximetry may result in displaying an SpO₂ value that has been clipped at

100%. In other words, the displayed values of SpO_2 may be limited to 100% to address concerns that displaying a value greater than 100% may be misleading or confusing. For example, such clipping may occur in situations where supplemental oxygen is being utilized to treat a patient, and, due to inaccuracies, a calculated value of SpO_2 exceeds 100%. Specifically, for example, the SpO_2 value may be determined to be 102% and this value may be clipped to indicate a maximum value of 100% because an actual value of SaO_2 exceeding 100% would not be valid.

However, it is now recognized that the usual 1% SpO_2 reporting precision and the practice of clipping may limit the ability to detect subtle reentrant respiratory phenomena via SpO_2 . Indeed, while pulse oximetry values of SpO_2 may be limited to ± 1 or 2% precision with respect to invasively measured values of SaO_2 , it has now been recognized that the trending accuracy of SpO_2 is substantially more accurate. Indeed, once a pulse oximeter sensor is in place and not moved between observations, the changes in SpO_2 values have been determined to be quite accurate. In other words, the changes or differences between SpO_2 values correspond closely to the value of the actual changes or differences in the related SaO_2 values. Accordingly, present embodiments are directed to measuring and trending SpO_2 values that are measured with a precision in the tenths, hundredths, thousandths, and so forth. This facilitates detecting accurate and precise changes in SpO_2 and utilization of such detected changes in monitoring, control, and analysis.

Additionally, present embodiments may eliminate the artificial ceiling of 100% for calculated and/or displayed SpO_2 values. By eliminating such clipping, the changes that occur above an SpO_2 value of 100% may be utilized in accordance with present embodiments. For example, in one embodiment, a change in an SpO_2 value from 101.24% to 100.75% may be significant for control and/or monitoring. Specifically, for example, such a change may be significant with regard to monitoring and/or controlling pO_2 , while remaining fairly insignificant with regard to monitoring SpO_2 . Thus, by eliminating the ceiling of 100% and using changing high resolution SpO_2 values, present embodiments may include monitoring and control features that would be unavailable based on the use of less precise and/or clipped SpO_2 values.

Some embodiments in accordance with the present disclosure relate to systems and methods that use high-precision, unclipped SpO_2 values for the detection and/or characterization of subtle SpO_2 variations and/or patterns that may be indicative of clinically significant pathologies. For example, present embodiments may utilize trending or relative comparisons of small and precise SpO_2 values over time for detection and/or characterization of conditions relating to obstructive and/or central sleep apnea, hypopnea, hyperpnea, and/or Cheyne-Stokes syndrome.

A specific example in accordance with present embodiments may include a system that is configured to detect and/or assess issues relating to sleep apnea. Sleep apnea is generally described as a sleep disorder that is characterized by episodes of paused breathing during sleep. These episodes of paused breathing may occur repeatedly throughout sleep, and each episode may last long enough to cause one or more breaths to be missed. Such episodes may be referred to as apneas. A typical apnea may include an interval between breaths of at least 10 seconds, with a neurological arousal and/or a blood oxygen desaturation of 3% or greater. The actual duration and severity of each apnea may substantially vary between multiple patients. Further, duration and severity of apneas may vary throughout a period of sleep for a single patient. Indeed, sleep apnea may have a wide range of severity. Accordingly,

it may be desirable to monitor precise SpO_2 levels, in accordance with present embodiments, to identify and/or assess potential indications of sleep apnea that could be overlooked by the less precise monitoring of traditional pulse oximetry systems. For example, small changes in SpO_2 levels over time may be utilized to ascertain subtle indications of sleep apnea.

Detection of subtle, yet pathological, SpO_2 variations may also be utilized in therapeutic systems and methods in accordance with present embodiments. In other words, changes occurring at high levels of precision, such as a change in the tenths or hundredths digit of a value of SpO_2 , may be utilized to initiate therapy, control certain treatments (e.g., a rate of supplying supplemental oxygen), alert a caregiver to certain patient conditions, and so forth. For example, subtle changes in SpO_2 detected with high precision measurement may be utilized to reduce and/or block patient-controlled analgesia (PCA), recommend or titrate continuous positive air pressure (CPAP) therapy, or enable fine automatic adjustment of mechanical ventilation parameters (e.g., FiO_2 , tidal volume, or respiratory rate). Indeed, such subtle changes may be utilized in a variety of different control algorithms to manage physiologic parameters and so forth.

One embodiment may include a system that is configured to control one or more physiologic parameters based on changes in the high precision component of the SpO_2 values or the like. Indeed, control of a patient's blood oxygen content with oxygen delivery is specifically discussed below as a particular example of present embodiments. However, one of ordinary skill in the art will recognize that this is merely one example and that different control parameters, delivery parameters, and the like may be utilized in accordance with present embodiments. For example, oxygen delivery may be adjusted based on a patient's estimated blood oxygen saturation level (SpO_2), oxygen delivery may be adjusted based on estimated pO_2 changes indicated by surrogate SpO_2 value changes, continuous positive airway pressure (CPAP) may be adjusted based on SpO_2 , and/or patient-controlled analgesia may be inhibited during periods of low SpO_2 . The small changes that are observable because of the added level of precision may facilitate such control mechanisms.

As indicated above, control of SpO_2 with oxygen delivery is presented herein as an example of a control feature in accordance with present embodiments. Specifically, FIG. 3 represents a system 200 including a controller 202 (e.g., a computer-based controller) that controls a composition and/or delivery amount of a gas mixture to a patient 204 to safely induce, maintain, and/or control the patient's SpO_2 level. Thus, in an example embodiment, a gas mixture supplied to the patient 204 may be considered the delivery parameter. For example, automatic adjustment of FiO_2 by the controller 202 may be utilized to control patient hypoxia or normoxia. FiO_2 may be defined as fractional inspired oxygen concentration or the percentage of oxygen in air inhaled by a patient through a ventilator. For example, in typical room air, the value for FiO_2 is approximately 21%.

In one embodiment a certain level of SpO_2 or pO_2 may be maintained within a narrow range by controlling based on the subtle changes in the high precision portion of the SpO_2 value (e.g., changes in a tenths, hundredths, or thousandths digit of an SpO_2 value). With regard to controlling pO_2 , it should be noted that SpO_2 is a surrogate for pO_2 in blood. Precise ranges of control may be achieved in accordance with present embodiments by increasing and or decreasing FiO_2 based on the subtle changes in the SpO_2 value.

Indeed, as indicated above, changes illustrated by trending values have been found to be accurate. In other words, a change in the value of SpO_2 over time is an accurate reflection

of the change in SaO_2 over the same time period) while the individual SpO_2 values themselves are not necessarily accurate representations of the SaO_2 value at each time. Thus, a change in the tenths, hundredths, or thousandths place of an SpO_2 value, or a change at a higher level of precision may be utilized to make adjustments and control a physiologic parameter. This can be especially useful for parameters that have large changes relative to smaller changes in SpO_2 levels, such as PO_2 . Such levels of control may assist in the prevention of certain issues that can arise due to inappropriate oxygen levels, such as retinopathy in neonates. Indeed, with regard to certain patients (e.g., neonates), a controller in accordance with present embodiments may maintain a very narrow range of SpO_2 levels, and, thus, pO_2 levels, to facilitate the avoidance of low oxygen level conditions associated with a risk for retinopathy, while avoiding high oxygen level conditions associated with lung development issues and the like.

The controller **202** may include a closed-loop FiO_2 controller that cooperates with a ventilator **206** to control the patient's SpO_2 value. Indeed, the controller **102** may receive input from a sensor **208** (e.g., a pulse oximeter sensor) that measures the patient's SpO_2 value at a high level of precision, and, based on a comparison of the measured SpO_2 value with a target SpO_2 value, manipulates the ventilator's output (e.g., FiO_2). For example, the FiO_2 controller **202** may output a request for increased FiO_2 from the ventilator **206** when a measured SpO_2 value is below a predefined SpO_2 target, or output a request for decreased FiO_2 from the ventilator **206** when the measured SpO_2 value is above the SpO_2 target. By increasing or decreasing FiO_2 , the patient's lungs may receive more or less oxygen, respectively, and the value of SpO_2 obtained from the patient will typically change correspondingly.

In accordance with present embodiments, detection of subtle variations in SpO_2 may be enhanced relative to the performance of traditional detectors by using an oximetry sensor that comprises light emitters with wavelengths selected for enhanced sensitivity to small changes in SpO_2 . For example, FIG. 4 illustrates a sensor **300** in accordance with present embodiments, wherein the sensor **300** includes a plurality of light emitters **302**. The plurality of light emitters **302** may include two or more emitters, wherein at least one of the light emitters **302** has a wavelength that facilitates detection of subtle variations in SpO_2 . Indeed, the sensor **300** may include an emitter that is optimized for detection of small changes in SpO_2 . Specifically, for example, the light emitters **302** may include a sensitivity optimized LED **304** that is capable of emitting light having a wavelength in the range of 600-680 nm. For example, in one embodiment, the LED **304** may emit light having a wavelength in the range of 600-620 nm. In another embodiment, the LED **304** may emit light having a wavelength near 660 nm. In the illustrated embodiment, the plurality of light emitters **302** includes the LED **304** and two other LEDs **306** and **308**. In some embodiments, only the LED **304** and a second LED may be utilized. For example, the LED **304**, which may be configured to emit light having a wavelength near 660 nm, may coordinate with the LED **306**, which may be configured to emit light having a wavelength near 950 nm, to detect subtle SpO_2 variations. In one embodiment, the two LEDs **306** and **308** illustrated in FIG. 4 may have wavelengths that are more traditional for pulse oximetry. In another embodiment the two LEDs **306** and **308** may be optimized to provide light at wavelengths that specifically compliment the sensitivity function of the LED **304**.

By including the LED **304**, the LED **306**, and/or the LED **308**, the sensor **300** may be highly sensitive to small quanti-

ties of deoxyhemoglobin in blood, and, therefore, highly sensitive to small changes in SpO_2 at values nears 100% SaO_2 . In other words, the light detected by a detector **310** of the sensor **300** may be largely impacted by small fluctuations in deoxyhemoglobin because of the nature of the light emitted by the LED **304**, the LED **306**, and/or the LED **308**. In the illustrated embodiment, the sensor **300** also includes a processor **314** that is capable of utilizing values related to detected light to calculate high resolution SpO_2 values and/or other blood characteristics.

FIG. 5A includes a chart **400**, which depicts absorption of oxyhemoglobin and deoxyhemoglobin plotted against wavelength. FIG. 5B includes a chart **500**, which depicts an absorption coefficient difference plotted against wavelength. FIG. 5C includes a chart **600**, which depicts a percent absolute coefficient difference plotted against wavelength. In the chart **400**, in accordance with one embodiment, a selected range for the LED **304** is indicated by arrow **402** and a selected range for a second LED, such as LED **306**, is indicated by arrow **404**. The greatest slope in the modulation ratio versus saturation (normalized to the modulation ratio at 95% SaO_2) may be achieved by pairing the largest and smallest values in the chart **600** (e.g., wavelengths of 660 and 1000 nm or greater). However, since the photo-response of silicon detectors decreases significantly beyond approximately 950 nm, a wavelength near 950 nm may be a practical value to use. Thus, the sensor **300** may be utilized with other features in accordance with present embodiments to facilitate detection, analysis, and control based on high resolution changes in SpO_2 values.

It should be noted that in other embodiments, the LED **304** may include and/or be coordinated with a green or yellow LED. For example, a green LED may have a wavelength of 500-570 nm and a yellow LED may have a wavelength of 570-600 nm. These wavelengths may be beneficial because their greater absorption of hemoglobin may enable the detection of a stronger pulsatile signal that facilitates resolution of smaller changes in SpO_2 . The encoder **140** should provide calibration information appropriate to whichever two or more wavelengths are used for calculation of SpO_2 or changes therein. Further, it should be noted adjusting the emitter-detector spacing may increase detection resolution. Indeed, moving the optics closer together in a reflectance design (though not so close as to create an optical shunt) may increase the slope of the modulation ratio relative to SaO_2 , as shown in FIG. 6, wherein a 2-mm spacing (instead of 10 mm) at 660/950 results in -6.6% change in the modulation ratio per % SaO_2 (versus -5.6% per % SaO_2).

While the embodiments set forth in the present disclosure may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. Indeed, the present techniques may not only be applied to measurements of blood oxygen saturation, but these techniques may also be utilized for the measurement and/or analysis of other blood constituents. For example, using the same, different, or additional wavelengths, the present techniques may be utilized in conjunction with the measurement and/or analysis of carboxyhemoglobin, met-hemoglobin, total hemoglobin, intravascular dyes, and/or water content. The disclosure is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure as defined by the following appended claims.

What is claimed is:

1. A pulse oximetry system, comprising:
a sensor comprising: an emitter configured to emit light at
different wavelengths into a tissue bed; and a detector
configured to detect the light from the emitter after dis-
persion and/or reflection by the tissue bed; and
a pulse oximeter configured to:
receive signals from the sensor that are indicative of
characteristics of the light detected by the detector;
utilize the signals to estimate blood oxygen saturation
values over time at a high resolution;
detect variations in the blood oxygen saturation values
that are smaller in magnitude than an accuracy, dis-
play precision, and/or calibration of the blood oxygen
saturation values; and
perform control and/or pattern detection functions based
on the variations.
2. The pulse oximetry system of claim 1, wherein the pulse
oximeter is configured to estimate the blood oxygen satura-
tion values with a precision of 0.1%, 0.01% or 0.001%.
3. The pulse oximetry system of claim 1, wherein the pulse
oximeter is configured to report changes in a value of partial
pressure of oxygen in blood based on the detection of varia-
tions in the blood oxygen saturation values.
4. The pulse oximetry system of claim 1, wherein the
emitter is configured to emit light having a wavelength in a
bounded range of 600-660 nm.
5. The pulse oximetry system of claim 4, wherein the
emitter comprises at least two light emitting diodes, wherein
one of the at least two light emitting diodes is configured to
emit light in the bounded range of 600-620 nm.
6. A method of performing pulse oximetry, comprising:
emitting light from an emitter component of a pulse oxime-
ter sensor at first and second wavelengths useful for
measuring oxygen saturation;
detecting the light with a detector component of the pulse
oximeter sensor;
transmitting signals indicative of characteristics of the
detected light to a pulse oximeter;
estimating blood oxygen saturation values over time at a
high resolution based on the signals with the pulse
oximeter;
detecting variations in the blood oxygen saturation values
that are smaller in magnitude than an accuracy, display
precision, and/or calibration of the blood oxygen satura-
tion values; and
detecting a patient condition and/or controlling a physi-
ologic parameter based on the variations.
7. The method of claim 6, wherein the first wavelength is
between 650-670 nm.

8. The method of claim 6, wherein the first wavelength is
within a range of 600-620 nm and the second wavelength is
within a range of 800-940 nm.

9. The method of claim 6, comprising controlling a partial
pressure of oxygen in a patient's blood based on the variations
in the blood oxygen saturation values.

10. The method of claim 9, wherein controlling the partial
pressure of oxygen comprises controlling delivery of oxygen
to the patient based on the variations in the blood oxygen
saturation values.

11. The method of claim 6, comprising identifying a pat-
tern indicative of sleep apnea based on the variations in the
blood oxygen saturation values.

12. The method of claim 6, comprising displaying the
blood oxygen saturation values at the high resolution on a
display screen.

13. A pulse oximeter sensor configured to facilitate detec-
tion of high precision changes in blood oxygen saturation
estimates obtained via pulse oximetry, comprising:

- a sensor body;
- a plurality of emitters positioned within the sensor body,
wherein each of the plurality of emitters is configured to
emit light at a different wavelength, and wherein at least
one of the plurality of emitters is selected for sensitivity
to small changes in blood oxygen saturation by emitting
light within a bounded range of wavelengths;
- a detector configured to detect the light emitted by the
plurality of emitters; and
- a processor configured to calculate a value of blood oxygen
saturation based on the detected light with a precision of
0.1, 0.01, or 0.001.

14. The pulse oximeter sensor of claim 13, wherein one of
the plurality of emitters is configured to emit light having a
wavelength in a bounded range of 600-620 nm.

15. The pulse oximeter sensor of claim 13, wherein one of
the plurality of emitters is configured to emit light having a
wavelength between 650-670 nm and another one of the
plurality of emitters is configured to emit light having a wave-
length between 940-1000 nm.

16. The pulse oximeter sensor of claim 14, wherein the
plurality of emitters comprise an orange LED configured to
emit light having a wavelength in a bounded range of 600-620
nm, and an infrared LED configured to emit light having a
wavelength in a bounded range of 800-940 nm.

17. The pulse oximeter sensor of claim 14, wherein the
plurality of emitters comprise an orange LED configured to
emit light having a wavelength in a bounded range of 600-620
nm, and a red LED configured to emit light having a wave-
length in a bounded range of 640-740 nm.

* * * * *

专利名称(译)	用于检测和分析生理参数变化的方法和设备		
公开(公告)号	US8509869	公开(公告)日	2013-08-13
申请号	US12/467003	申请日	2009-05-15
[标]申请(专利权)人(译)	内尔科尔普里坦贝内特公司		
申请(专利权)人(译)	NELLCOR PURITAN BENNETT LLC		
当前申请(专利权)人(译)	COVIDIEN LP		
[标]发明人	BAKER JR CLARK R MANNHEIMER PAUL D		
发明人	BAKER, JR., CLARK R. MANNHEIMER, PAUL D.		
IPC分类号	A61B5/00		
CPC分类号	A61B5/14551		
其他公开文献	US20100292548A1		
外部链接	Espacenet USPTO		

摘要(译)

本公开一般涉及识别和/或分析测量的生理参数中的高分辨率变化，例如使用脉搏血氧测量法测量的血氧饱和度（SpO₂）。本实施例可以包括一种系统，该系统包括传感器，该传感器包括能够将不同波长的光发射到组织床中的发射器，以及能够在组织床分散和/或反射之后检测来自发射器的光的检测器。此外，该系统可以包括脉冲血氧计，其能够接收来自传感器的信号，该信号指示由检测器检测到的光的特性，并且利用该信号以高分辨率随时间估计血氧饱和度值以便于检测变化。在血氧饱和度值中，血氧饱和度值的大小小于精确度，显示精度和/或血氧饱和度值的校准。

